Literature DB >> 10644547

Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats.

W Tavares1, D J Drucker, P L Brubaker.   

Abstract

The intestinotropic hormone glucagon-like peptide (GLP)-2-(1-33) is cleaved in vitro to GLP-2-(3-33) by dipeptidyl peptidase IV (DP IV). To determine the importance of DP IV versus renal clearance in the regulation of circulating GLP-2-(1-33) levels in vivo, GLP-2-(1-33) or the DP IV-resistant analog [Gly(2)]GLP-2 was injected in normal or DP IV-negative rats and assayed by HPLC and RIA. Normal rats showed a steady degradation of GLP-2-(1-33) to GLP-2-(3-33) over time, whereas little or no conversion was detected for GLP-2-(1-33) in DP IV-negative rats and for [Gly(2)]GLP-2 in normal rats. To determine the role of the kidney in clearance of GLP-2-(1-33) from the circulation, normal rats were bilaterally nephrectomized, and plasma immunoreactive GLP-2 levels were measured. The slope of the disappearance curves for both GLP-2-(1-33) and [Gly(2)]GLP-2 were significantly reduced in nephrectomized compared with non-nephrectomized rats (P < 0.01). In contrast to both GLP-2-(1-33) and [Gly(2)]GLP-2, GLP-2-(3-33) did not stimulate intestinal growth in a murine assay in vivo. Thus the intestinotropic actions of GLP-2-(1-33) are determined both by the actions of DP IV and by the kidney in vivo in the rat.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10644547     DOI: 10.1152/ajpendo.2000.278.1.E134

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  17 in total

Review 1.  Gut adaptation and the glucagon-like peptides.

Authors:  D J Drucker
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

2.  Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.

Authors:  D Marguet; L Baggio; T Kobayashi; A M Bernard; M Pierres; P F Nielsen; U Ribel; T Watanabe; D J Drucker; N Wagtmann
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

Review 3.  Ghrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis.

Authors:  Charlotte X Dong; Patricia L Brubaker
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-10-02       Impact factor: 46.802

4.  Enteral nutrients potentiate glucagon-like peptide-2 action and reduce dependence on parenteral nutrition in a rat model of human intestinal failure.

Authors:  Adam S Brinkman; Sangita G Murali; Stacy Hitt; Patrick M Solverson; Jens J Holst; Denise M Ney
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-06-28       Impact factor: 4.052

Review 5.  Gut hormones, and short bowel syndrome: the enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation.

Authors:  G-R Martin; P-L Beck; D-L Sigalet
Journal:  World J Gastroenterol       Date:  2006-07-14       Impact factor: 5.742

Review 6.  Growth factors: possible roles for clinical management of the short bowel syndrome.

Authors:  Mark E McMellen; Derek Wakeman; Shannon W Longshore; Lucas A McDuffie; Brad W Warner
Journal:  Semin Pediatr Surg       Date:  2010-02       Impact factor: 2.754

Review 7.  Intestinal hormones and growth factors: effects on the small intestine.

Authors:  Laurie Drozdowski; Alan B R Thomson
Journal:  World J Gastroenterol       Date:  2009-01-28       Impact factor: 5.742

8.  Pharmacokinetics of teduglutide in subjects with renal impairment.

Authors:  Rüdiger Nave; Atef Halabi; Rolf Herzog; Peter Schaffer; Jörg Diefenbach; Stephan Krause; Peter Berghöfer; Gezim Lahu; Manfred Hartmann
Journal:  Eur J Clin Pharmacol       Date:  2012-11-28       Impact factor: 2.953

9.  Glucagon-like peptide 2 (GLP-2) in bovine colostrum and transition milk.

Authors:  Yudai Inabu; Hiroshi Yamamoto; Haruki Yamano; Yutaka Taguchi; Shunnosuke Okada; Tetsuji Etoh; Yuji Shiotsuka; Ryoichi Fujino; Hideyuki Takahashi
Journal:  Heliyon       Date:  2021-05-15

10.  GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model.

Authors:  Susan E Alters; Bryant McLaughlin; Benjamin Spink; Tigran Lachinyan; Chia-wei Wang; Vladimir Podust; Volker Schellenberger; Willem P C Stemmer
Journal:  PLoS One       Date:  2012-11-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.